DEFINIUM THERAPEUTICS INC
DFTXNASDAQTrading Snapshot
- Day Range
- $40.32 – $41.71
- 52-Week Range
- $8.70 – $49.70
- Volume
- $2.51B
- Avg Volume
- $2.37B
- Shares Outstanding
- 124.6M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $455M
- Last Q Revenue
- $112M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.43
- Dividend Yield
- —
Why Investors Own DFTX
- ✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About DEFINIUM THERAPEUTICS INC
A company profile for DEFINIUM THERAPEUTICS INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $75
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $73 to $75.
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsRobert Barrow - CEO & DirectorDaniel Karlin -...
Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge
Definium Therapeutics (DFTX) Q2 loss of $1.44/share misses estimates; stock dips 4.7% after-hours despite positive Phase 3 MDD data and $1.1B cash.
Wells Fargo Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $68
Wells Fargo analyst Benjamin Burnett initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $68.
Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $73
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $48 to $73.
Why Is GH Research Stock Trading Higher on Thursday?
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.